<DOC>
	<DOCNO>NCT00118677</DOCNO>
	<brief_summary>This trial aim study safety long term supervise treatment interruption HIV infect patient CD4 350/mm3 plasma HIV RNA 50 000/mL . Another aim study assess immunological virological factor associate duration treatment interruption .</brief_summary>
	<brief_title>Long-Term Supervised Treatment Interruption HIV-Infected Patients</brief_title>
	<detailed_description>The limitation drug use HIV include toxicity , tolerability , propensity induce resistance take absolute regularity cost . Treatment interruption patient receive antiretroviral treatment set chronic infection associate viral rebound rapid CD4 T cell decrease conduct antiretroviral therapy restart . In patient high CD4+ cell count ( patient receive treatment chronic infection control viremia patient receive HAART treatment would start base current guideline ) , evaluate safety long term supervise treatment interruption . Another aim study assess immunological virological factor associate duration treatment interruption ( proviral HIV DNA baseline follow-up , plasma HIV RNA baseline follow-up , CD4 T cell CD8 T cell HIV specific response baseline 12 month ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Males non pregnant female 18 year age older Who confirm laboratory diagnosis HIV infection Started first line antiretroviral treatment CD4 350/mm3 plasma HIV RNA 50 000/mL Ongoing Antiretroviral therapy inclusion CD4 450/mm3 plasma HIV RNA 5000/mL HBVHIV coinfection receive lamivudine therapy Ongoing immunotherapy include IL2 , interferon HIV specific vaccine Pregnancy project pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>HIV Infections</keyword>
</DOC>